Carolyn Bertozzi returns to Lilly board of directors
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) elected Carolyn R. Bertozzi, Ph.D. to its board of directors effective Dec. 8, 2025. She will serve on the board's Science and Technology and Ethics and Compliance committees. Dr. Bertozzi is a Nobel Prize-winning chemist and currently serves as Baker Family director of Sarafan ChEM-H and professor at Stanford, and is an Investigator of the Howard Hughes Medical Institute.
Dr. Bertozzi previously served on Lilly's board from 2017 to 2021 and is an elected member of the National Academy of Medicine, National Academy of Sciences, and American Academy of Arts and Sciences.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, LLY declined 1.26%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
LLY was up 1.16% while peers showed mixed moves (e.g., JNJ +1.01%, ABBV -0.69%, AZN -0.36%), suggesting stock-specific strength rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 09 | Manufacturing expansion | Positive | -1.5% | Announced >$6B Alabama API facility and major U.S. manufacturing buildout. |
| Dec 09 | M&A acquisition | Positive | -1.5% | Completion of Adverum tender offer with cash and CVR consideration. |
| Dec 09 | Clinical trial data | Positive | -1.5% | Phase 3 Jaypirca data showing 80% reduction in progression or death risk. |
| Dec 08 | Dividend declaration | Positive | -1.3% | Declared Q1 2026 dividend of $1.73 per share with set pay date. |
| Dec 08 | Board appointment | Positive | -1.3% | Reappointed Nobel laureate Carolyn Bertozzi to key board committees. |
Recent news items with broadly positive or strategic tones have coincided with negative next-day price moves, indicating a pattern of divergence between news tone and short-term price reaction.
Over the last few days, Lilly announced a $6 billion Alabama API facility targeting completion in 2032, the completion of its Adverum acquisition tender offer, and strong Phase 3 data for Jaypirca in CLL/SLL. It also declared a $1.73 per-share first-quarter 2026 dividend and disclosed Carolyn Bertozzi’s return to the board effective Dec. 8, 2025. Despite these generally constructive updates, the stock saw 24-hour reactions between about -1.26% and -1.54%, highlighting short-term selling into good news.
Market Pulse Summary
This announcement adds Nobel-level scientific expertise to Lilly’s board, with Carolyn Bertozzi serving on the Science and Technology and Ethics and Compliance committees effective Dec. 8, 2025. It follows a series of strategically positive updates, including major manufacturing investment, an acquisition, and strong clinical data. Investors may watch how this governance move supports Lilly’s oncology and immunology pipeline, alongside any future insider filings or leadership changes that further shape board composition.
AI-generated analysis. Not financial advice.
"On behalf of Lilly and the entire board, I would like to welcome Carolyn back to Lilly," said David A. Ricks, Lilly chair and CEO. "Carolyn is a Nobel Prize-winning chemist whose work has fundamentally changed how we think about developing targeted medicines, particularly in cancer. As we continue to pioneer new approaches in oncology and immunology, her perspective will be invaluable. We're fortunate to have her back as we work to deliver more breakthrough medicines to patients."
Currently serving as the Baker Family director of Sarafan ChEM-H, Anne T. and Robert M. Bass professor in the School of Humanities and Sciences and professor, by courtesy, of Chemical and Systems Biology and of Radiology at
She has been recognized with many honors and awards for her research accomplishments and is an elected member of the National Academy of Medicine, National Academy of Sciences and American Academy of Arts and Sciences.
Dr. Bertozzi previously served on Lilly's board from 2017 to 2021.
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. C-LLY
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) including about research and related initiatives and reflects Lilly's current beliefs and expectations. However, as with any such undertaking, there are substantial risks and uncertainties in the research and development process, manufacturing process, development and commercialization of pharmaceutical products any of which could impact the overall commercial success of our products, and as related to cost, completion timing, expected capacity, personnel, and other factors which could impact expected benefits of the capacity expansion and related initiatives. For further discussion of risks and uncertainties relevant to Lilly's business that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
Refer to: | Carrie Munk; munk_carrie@lilly.com; 317-416-2393 (Media) |
Michael Czapar; czapar_michael_c@lilly.com; 317-617-0983 (Investors) |
View original content to download multimedia:https://www.prnewswire.com/news-releases/carolyn-bertozzi-returns-to-lilly-board-of-directors-302634817.html
SOURCE Eli Lilly and Company
FAQ
Who is Carolyn R. Bertozzi and why was she elected to Lilly's board (LLY) on Dec. 8, 2025?
What committees will Dr. Bertozzi join at Eli Lilly (LLY)?
Did Carolyn Bertozzi previously serve on the Lilly board (LLY) and when?
What are Carolyn Bertozzi's current academic and research roles noted in the Dec. 8, 2025 announcement?
Will Carolyn Bertozzi's return to Lilly's board (LLY) affect the company's leadership in oncology and immunology?
